SCT Annual Meeting Presentations & Videos

Discover SCT's Scientific Knowledge-Bank

  175 Learning Opportunities Found

Michael S. Lauer
2015 (Arlington) Annual Meeting
Founders Lecture
A Future for Clinical Trials? An NIH Perspective
Study Team
2015 (Arlington) Annual Meeting
Trial of the Year Award
Mechanical versus Manual Chest Compression for Out-of-Hospital Cardiac Arrest (PARAMEDIC)
James D. Neaton
2015 (Arlington) Annual Meeting
Curtis Meinert Lecture
International Trials and Tribulations
Steve Goodman
2015 (Arlington) Annual Meeting
Special Presentation
Remembering David Sackett
Cook et al
2015 (Arlington) Annual Meeting
Special Presentation
Workshop - Conducting Valid Trials: the Critical (and Misunderstood) Roles of Randomization and Complete Follow-Up
Jennifer Gassman
2015 (Arlington) Annual Meeting
Fellows Presentation
Presentation of the Class of 2015 Fellows
KyungMann Kim
2015 (Arlington) Annual Meeting
Presidential Welcome
Shona Silvester
2015 (Arlington) Annual Meeting
Contributed Session
‘MINIMUM TIME/MAXIMUM QUALITY’: AUTOMATED TRACKING SYSTEMS TO IMPROVE EFFICIENCY, REDUCE THE RISK OF HUMAN ERROR AND ENSURE TIMELY DATA COLLECTION
Edward Gaunt
2015 (Arlington) Annual Meeting
Contributed Session
A Centralized Approach to Mailing and Materials Distribution in the Gulf Long-Term Follow-up Study (GuLF STUDY)
Raymond Carragher
2015 (Arlington) Annual Meeting
Contributed Session
A COMPARISON OF SOME METHODS FOR DETECTION OF SAFETY SIGNALS IN RANDOMISED CONTROLLED TRIALS
Danila Azzolina
2015 (Arlington) Annual Meeting
Contributed Session
A decision making tool for non-pharmacological treatment in knee osteoarthritis
Dong-Yun Kim
2015 (Arlington) Annual Meeting
Contributed Session
A fully sequential test for treatment effects using censored data in multi-center clinical trials
Giulia Lorenzoni
2015 (Arlington) Annual Meeting
Contributed Session
A latent Gamma model for modelling the simultaneous effect of treatment on WOMAC subscales in osteoarthritis RCTs
Qian Wu
2015 (Arlington) Annual Meeting
Contributed Session
A New Approach of Incorporating Biomarker Information to Identify Patient Subgroups with Enhanced Treatment Effect for Personalized Medicine
Doussau Adelaide
2015 (Arlington) Annual Meeting
Contributed Session
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
Matthew Liang
2015 (Arlington) Annual Meeting
Contributed Session
A NOVEL USER SURVEY TO DETERMINE A CLINICALLY MEANINGFUL EFFECT SIZE IN THE PLANNING OF CSP#590 (Li+)
Jieling Miao
2015 (Arlington) Annual Meeting
Contributed Session
A SIMPLE APPROACH FOR INCORPORATING MULTIPLE TOXICITY THRESHOLDS IN PHASE I TRIALS
Jonathan Cook
2015 (Arlington) Annual Meeting
Contributed Session
A systematic review of the use of an expertise-based randomised trial design
Melanie Prague
2015 (Arlington) Annual Meeting
Contributed Session
Accounting for informative missingness, interaction and interference in cluster randomized trials.
Nolan Wages
2015 (Arlington) Annual Meeting
Contributed Session
Adaptive designs for early-phase oncology trials of combined immunotherapy regimens
Yuko Palesch
2015 (Arlington) Annual Meeting
Contributed Session
Adaptive first interim analysis design
David Gillespie
2015 (Arlington) Annual Meeting
Contributed Session
ADHERENCE-ADJUSRED ESTIMATES OF BENEFITS AND HARMS FROM TREATMENT WITH AMOXICILLIN FOR LOWER-RESPIRATORY-TRACT-INFECTION: SECONDARY ANALYSIS OF A 12-COUNTRY RANDOMISED PLACEBO-CONTROLLED TRIAL USING RANDOMISATION-BASED EFFICACY ESTIMATORS
Nariman Sepehrvand
2015 (Arlington) Annual Meeting
Contributed Session
Alignment of Site versus Adjudication Committee-based diagnoses with the patients’ outcome: Lessons learned from PROACT-3 trial
Gillian Gresham
2015 (Arlington) Annual Meeting
Contributed Session
Alternative Approaches to the Analysis of Toxicities in Randomized Clinical Trials
Marisa De Rosa
2015 (Arlington) Annual Meeting
Contributed Session
AN ONLINE DRUG REGISTRY EXPERIENCE IN ITALY TO SUPPORT MONITORING AND REIMBURSEMENT OF INNOVATIVE DRUGS
Jason Stock
2015 (Arlington) Annual Meeting
Contributed Session
Applying DM Processes to Research Networks and How it Differs from “Traditional” Clinical Trials
Dario Gregori
2015 (Arlington) Annual Meeting
Contributed Session
Assessing heterogeneity of treatment effect in case of unobserved covariates via conditional frailty models
Heather Murray
2015 (Arlington) Annual Meeting
Contributed Session
Assessing impact on post-trial cardiovascular admissions, operations and procedures using routinely collected health records: Illustrated by the 20 year follow-up of the West of Scotland Coronary Prevention Study
Sarah Leatherman
2015 (Arlington) Annual Meeting
Contributed Session
Assessing the Data Quality of a Clinical Trial Directly Embedded within the Electronic Medical Record: the Department of Veterans Affairs’ Point-of-Care Clinical Trial Experience
Patsamon Rerksirikul
2015 (Arlington) Annual Meeting
Contributed Session
Association between Years of Clinical Trial Experience and Quality of Study data: Findings from HIV Research Centers in Thailand
Stacey Slone
2015 (Arlington) Annual Meeting
Contributed Session
Automated Reminders Promote Completion of Long-Term Radon Tests in a Lung Cancer Study
Renee Stewart
2015 (Arlington) Annual Meeting
Contributed Session
BARRIERS AND CHALLENGES TO PARTICIPANT RECRUITMENT IN A RANDOMIZED CONTROLLED TRIAL ON ADVANCED CANCER PATIENTS
Deokumar Srivastava
2015 (Arlington) Annual Meeting
Contributed Session
Beyond the Assumption of Constant Hazard Rate in Estimating Incidence Rate on Current Status Data with Applications to Phase IV Cancer Trial
Soe Soe Thwin
2015 (Arlington) Annual Meeting
Contributed Session
Biostatistical Considerations for VA Cooperative Study #590, “Double-Blind Placebo-Controlled Study of Lithium for Preventing Repeated Suicidal Self-Directed Violence in Patients with Depression or Bipolar Disorder”
Kerry Avery
2015 (Arlington) Annual Meeting
Contributed Session
BLINDING IN SURGICAL TRIALS IS POSSIBLE: EXPERIENCES FROM THE ROMIO FEASIBILITY STUDY
Catherine Dillon
2015 (Arlington) Annual Meeting
Contributed Session
Building a Strong Data Management Center for the National Institutes of Health’s Stroke Trials Network
Steven Julious
2015 (Arlington) Annual Meeting
Contributed Session
Case Studies and Exemplars of Efficient Study Designs in Clinical Trials
Paul Thompson
2015 (Arlington) Annual Meeting
Contributed Session
Causal analyses of randomized clinical trials improves understanding
Todd MacKenzie
2015 (Arlington) Annual Meeting
Contributed Session
CAUSAL HAZARD RATIO ESTIMATION USING PRINCIPAL STRATIFICATION
Trisha Boekhoudt
2015 (Arlington) Annual Meeting
Contributed Session
CHALLENGES IN DATA MANAGEMENT FOR CONSORTIA
Lijuan Zeng
2015 (Arlington) Annual Meeting
Contributed Session
CHARACTERIZING REPORTING OF PHASE 3 CROSSOVER TRIALS REGISTERED ON CLINICALTRIALS.GOV
Elizabeth Gargon
2015 (Arlington) Annual Meeting
Contributed Session
CHOOSING IMPORTANT HEALTH OUTCOMES FOR COMPARATIVE EFFECTIVENESS RESEARCH: A SYSTEMATIC REVIEW
Abhinav Sharma
2015 (Arlington) Annual Meeting
Contributed Session
Clinical outcomes and biomarker expression patterns in diabetics with heart failure: novel insights from the COACH study
Emily Dressler
2015 (Arlington) Annual Meeting
Contributed Session
Clinical trial interim strategies for rare even outcomes using Poisson distributions: Extension of Bayesian predictive probability designs
Abigail Shoben
2015 (Arlington) Annual Meeting
Contributed Session
Consent bias in cluster randomized trials: Should we be concerned?
Carol Van Huysen
2015 (Arlington) Annual Meeting
Contributed Session
Consideration and Early Barrier Assessment for use of Electronic Health Record Access for Remote Source Document Verification in a Clinical Trials Network
Lauren Yesko
2015 (Arlington) Annual Meeting
Contributed Session
Creating a Comprehensive Clinical Trial Management System
Shannon McDonough
2015 (Arlington) Annual Meeting
Contributed Session
CURRENT STATUS AND LESSONS LEARNED FROM THE IMPLEMENTATION OF THE SWOG LUNG MASTER PROTOCOL
Elizabeth Wright
2015 (Arlington) Annual Meeting
Contributed Session
DATA AND SAMPLE REPOSITORIES – HOW ARE ARCHIVED DATA SETS BEING USED?
Katelyn Garcia
2015 (Arlington) Annual Meeting
Contributed Session
DATA COLLECTION AND CLEANING FOR PARTICIPANT ENTERED MEDICATIONS: THE STUDY OF NOVEL APPROACHES TO PREVENTION CLINICAL TRIAL
William Meurer
2015 (Arlington) Annual Meeting
Contributed Session
Department of Emergency Medicine; Department of Neurology, University of Michigan, Ann Arbor Overview
Tracee Williams
2015 (Arlington) Annual Meeting
Contributed Session
DESIGN AND IMPLEMENTATION OF A DYNAMIC AND ELECTRONIC DELEGATION OF STUDY RESPONSIBILITIES AND SIGNATURE LOG
Bryan Comstock
2015 (Arlington) Annual Meeting
Contributed Session
DESIGNING A RANDOMIZED CONTROLLED TRIAL WITH CONTINUOUS PATIENT REPORTED OUTCOMES USING A MINIMALLY CLINICALLY IMPORTANT RESPONSE DERIVED EFFECT SIZE
Nicole Cockayne
2015 (Arlington) Annual Meeting
Contributed Session
DESIGNING AND IMPLEMENTING A RANDOMISED CONTROLLED TRIAL EVALUATING AN ADJUNCTIVE INTERNET-DELIVERED COGNITIVE BEHAVIOURAL THERAPY PROGRAM ON OUTCOMES OF STANDARD TREATMENT FOR DEPRESSION: UNIQUE CHALLENGES AND LESSONS LEARNED
Amy Whitehead
2015 (Arlington) Annual Meeting
Contributed Session
Designing Randomised Controlled Trials based on Pilot Trials: Statistical Issues and Challenges
Janice Pogue
2015 (Arlington) Annual Meeting
Contributed Session
Detecting unreported hospitalizations in a multi-national RCT: Looking for a needle in a haystack?
David Gillespie
2015 (Arlington) Annual Meeting
Contributed Session
DETERMINING MAXIMAL INTERVENTION BENEFIT IN PUBLIC HEALTH TRIALS USING RANDOMISATION-BASED EFFICACY ESTIMATORS
Lauren Yesko
2015 (Arlington) Annual Meeting
Contributed Session
Developing a Site Training and Troubleshooting Plan in the Digital Age
Roberta Scherer
2015 (Arlington) Annual Meeting
Contributed Session
Developing the protocol for the standard-of-care treatment arm of the Tinnitus Retraining Therapy Trial
Kerry Avery
2015 (Arlington) Annual Meeting
Contributed Session
DEVELOPMENT OF A CORE OUTCOME SET FOR TRIALS IN OESOPHAGEAL CANCER SURGERY
Larisa Tereshchenko
2015 (Arlington) Annual Meeting
Contributed Session
Development of an arrhythmia patient council to improve patient engagement and patient centeredness in clinical cardiac electrophysiology research
Mae Gordon
2015 (Arlington) Annual Meeting
Contributed Session
Diagnostic Misclassification: Possible Explanation for Unsuccessful Therapeutic Trials of 'Pink Eye’
Mayumi Fukuda-Doi
2015 (Arlington) Annual Meeting
Contributed Session
DIFFERENCES IN REGULATORY SYSTEMS GOVERNING CLINICAL TRIALS- COMPARISON BETWEEN JAPAN AND US
Munyaradzi Dimairo
2015 (Arlington) Annual Meeting
Contributed Session
Differential reporting of group sequential randomised controlled trials (GS RCT): shortcomings of the CONSORT 2010 statement
Ravi Ramjeesingh
2015 (Arlington) Annual Meeting
Contributed Session
Disease Risk Scores: Use in a Retrospective Analysis Regarding Correlation between Time to Adjuvant Chemotherapy Treatment (TTAC) and Disease Outcomes in Early Breast Cancer.
William Aitchison
2015 (Arlington) Annual Meeting
Contributed Session
EDC database driven rule based logic - benefits and potential
Chengwu Yang
2015 (Arlington) Annual Meeting
Contributed Session
Effects of preterm delivery and early intervention on infants’ mental development: A randomized controlled two-year follow-up study
Adelaide Doussau
2015 (Arlington) Annual Meeting
Contributed Session
Ethical tension in cancer randomized controlled trials using placebo: a review of recently published trials.
Manoj Humagain
2015 (Arlington) Annual Meeting
Contributed Session
EVALUATION OF ASSOCIATION BETWEEN THE PREVALENCE AND SEVERITY OF PERIODONTAL DISEASES AND ABO BLOOD GROUPS AMONG NEPALESE ADULTS
Zhaoyang Teng
2015 (Arlington) Annual Meeting
Contributed Session
Evaluation of Imposing an Additional Requirement and Sample Size Planning for Multi-Regional Clinical Trials.
Katie Gillies
2015 (Arlington) Annual Meeting
Contributed Session
EvaLuation of Interventions for informed Consent for randomIsed controlled Trials (ELICIT): developing a core outcome set.
Julia Brown
2015 (Arlington) Annual Meeting
Contributed Session
Experience and Benefits arising from The United Kingdom Registered Clinical Trials Unit Network : J Brown on behalf of the UKCRC Registered Clinical Trials Unit Executive
Allan Hackshaw
2015 (Arlington) Annual Meeting
Contributed Session
Experience from a national randomized phase III trial to prospectively evaluate a predictive biomarker for chemotherapy, in patients with advanced non-small cell lung cancer
Letitia Perdue
2015 (Arlington) Annual Meeting
Contributed Session
Form Design for Participant Data Entry: The Study of Novel Approaches to Prevention Clinical Trial
Wen Wan
2015 (Arlington) Annual Meeting
Contributed Session
Graphic Illustration of Interaction Analysis of Three Combination Drugs via a Modified Genetic Algorithm
Koko Asakura
2015 (Arlington) Annual Meeting
Contributed Session
Group-sequential strategies for clinical trials with co-primary endpoints
Katharine Cooper-Arnold
2015 (Arlington) Annual Meeting
Contributed Session
HOW CAN CLINICAL TRIAL METRICS IMROVE PERFORMANCE AND FUNDER/GRANTEE COMMUNICATION: THE NIH PERSPECTIVE
Kerry Avery
2015 (Arlington) Annual Meeting
Contributed Session
HOW CAN PILOT WORK OPTIMALLY INFORM SURGICAL RCTS? A REVIEW OF CURRENT EVIDENCE
Katie Neville
2015 (Arlington) Annual Meeting
Contributed Session
HOW CAN WE DELIVER OPTIMUM BENEFITS FOR PATIENTS? MAXIMISING EFFICIENCY WITH A SEAMLESS PHASE II/III TRIAL DESIGN
Alison McDonald
2015 (Arlington) Annual Meeting
Contributed Session
How can we improve the efficiency of trial conduct? Views of UK Clinical Trials Units staff
Amy Mhatre-Owens
2015 (Arlington) Annual Meeting
Contributed Session
How To Prepare An Informative And Thorough DSMB Report
Ian Saldanha
2015 (Arlington) Annual Meeting
Contributed Session
Impact of author conflicts of interest on full publication of RCTs presented at conferences
Qiyuan Shi
2015 (Arlington) Annual Meeting
Contributed Session
IMPACT OF PUBLICATION BIAS ON NETWORK META-ANALYSIS: A NETWORK META-ANALYSIS OF PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION DRUGS USING AVAILABLE PUBLIC DATA FROM FDA CLINICAL REVIEWS
Matthew Wright
2015 (Arlington) Annual Meeting
Contributed Session
IMPLEMENTATION OF A MEDICATION AND SUPPLY INVENTORY AND RESUPPLY PROCESS - INCREASING THE EFFICIENCY OF THE TRACKING AND DISTRIBUTION OF SUPPLIES IN CLINICAL TRIALS
John Podoba
2015 (Arlington) Annual Meeting
Contributed Session
Implementation of a Web-based Minimization Algorithm for Patient Allocation in Clinical Trials
Jaemyung Kim
2015 (Arlington) Annual Meeting
Contributed Session
Implementation of Advanced Randomization Algorithm with Integrated Study Drug Tracking
Kenneth Schechtman
2015 (Arlington) Annual Meeting
Contributed Session
IMPROVED HEALTH THROUGH EFFICIENT WOOD BURNING COOKSTOVES IN RURAL INDIA: DESIGN OF A CLUSTER RANDOMIZED TRIAL
Joerg Hasford
2015 (Arlington) Annual Meeting
Contributed Session
In multinational trials adverse reactions should be analysed by country or region too.
Eric Foster
2015 (Arlington) Annual Meeting
Contributed Session
INCLUDING UNCERTAINTY IN THE TARGET PROBABILITY OF DOSE LIMITING TOXICITY IN PHASE I/II STUDIES WITH A DOSE FINDING COMPONENT
Maiken Pontoppidan
2015 (Arlington) Annual Meeting
Contributed Session
INCREDIBLE YEARS PARENTS AND BABIES – A RANDOMIZED CONTROLLED TRIAL OF A PARENTING INTERVENTION IN DENMARK
Kaleab Abebe
2015 (Arlington) Annual Meeting
Contributed Session
Informative Censoring in the HALT-PKD Study B Trial
Zackary Lemka
2015 (Arlington) Annual Meeting
Contributed Session
Integrated Electronic Data Monitoring System for Multi-center Clinical Trials
Erik Doffagne
2015 (Arlington) Annual Meeting
Contributed Session
Integrating Central Statistical Monitoring (CSM) in a Quality by Design (QbD) approach for Clinical Trials
Sarah Brown
2015 (Arlington) Annual Meeting
Contributed Session
INTERIM SAMPLE SIZE RE-ESTIMATION: SAFEGUARDING THE POWER OF A TRIAL
Valeriya Lockwood
2015 (Arlington) Annual Meeting
Contributed Session
INTERNATIONAL CLINICAL TRIALS: IMPLEMENTATION, COORDINATION, AND OBSTACLES
Suzanne Hartley
2015 (Arlington) Annual Meeting
Contributed Session
Is dedication all you need to deliver to time and target in a multicentre study? Lessons learned from the UK Prevention of Delirium (POD) study
Isabelle Smith
2015 (Arlington) Annual Meeting
Contributed Session
Is pain a predictor of Category 2 pressure ulcers? Comparison of methods used to analyse data from the PURPOSE Pain Cohort Study
Jonathan Gibb
2015 (Arlington) Annual Meeting
Contributed Session
Laboratory Information Management Systems for academic trials with complex/multiple cohorts
Niravath Polly
2015 (Arlington) Annual Meeting
Contributed Session
LESSONS LEARNED FROM ULTRA-SENSITIVE ESTRADIOL QUANTITATION
Polly Niravath
2015 (Arlington) Annual Meeting
Contributed Session
LESSONS LEARNED FROM ULTRA-SENSITIVE ESTRADIOL QUANTITATION
SETH OKEYO
2015 (Arlington) Annual Meeting
Contributed Session
MANAGING CLINICAL DATA QUERIES USING AN IN-HOUSE BUILT QUERY MANAGEMENT SYSTEM- QMSPlus
Francesca Fiorentino
2015 (Arlington) Annual Meeting
Contributed Session
Managing multiple outcomes in early phase trials
Lauren Yesko
2015 (Arlington) Annual Meeting
Contributed Session
Measuring Treatment Adherence and Exposure, and Study Completion
Donald Taves
2015 (Arlington) Annual Meeting
Contributed Session
MINIMIZATION CAN PREVENT SELECTION BIAS
Graeme MacLennan
2015 (Arlington) Annual Meeting
Contributed Session
Missing data in multi-item patient reported outcome measures: a case study using the the Oxford Knee Score
Paola Berchialla
2015 (Arlington) Annual Meeting
Contributed Session
Modeling QoL in osteoarthritis as an RCT outcome using skewed truncated distributions
James Moon
2015 (Arlington) Annual Meeting
Contributed Session
MONITORING ACCRUAL ON THE SWOG LUNG MASTER PROTOCOL
Talat Almukhtar
2015 (Arlington) Annual Meeting
Contributed Session
MONITORING OF ADVERSE EVENTS REPORTING IN MULTICENTER CLINICAL TRIALS USING A MIXED EFFECT REGRESSION MODEL
Monica Shah
2015 (Arlington) Annual Meeting
Contributed Session
NHLBI Heart Failure Network: Turning the Curve on Enrollment in Heart Failure Trials
Chengwu Yang
2015 (Arlington) Annual Meeting
Contributed Session
On the relationship between the Modified Rankin Scale (mRS) and the NIH Stroke Scale (NIHSS)
Jincheng Shen
2015 (Arlington) Annual Meeting
Contributed Session
Optimal Treatment Regime Estimation in Prostate Cancer Recurrence Management Using Random Forests
Kerry Avery
2015 (Arlington) Annual Meeting
Contributed Session
OPTIMISING THE DESIGN OF INTERNAL PILOT WORK TO INFORM EFFICIENT RANDOMISED CONTROLLED TRIALS: ISSUES TO CONSIDER WHEN DEVELOPING PROGRESSION CRITERIA
Kabir Soeny
2015 (Arlington) Annual Meeting
Contributed Session
Optimizing Dose Regimens and Fixed Dose Combination Ratios for a Target Concentration
Lynda Constable
2015 (Arlington) Annual Meeting
Contributed Session
Overcoming a Trial ‘Adverse Event’: impact and experiences of a temporary suspension of a clinical trial
Qian Shi
2015 (Arlington) Annual Meeting
Contributed Session
Performances of modified trial-level surrogacy estimates in binary-survival endpoint scenario
Francesca Fiorentino
2015 (Arlington) Annual Meeting
Contributed Session
Pharmacological Interventions for the Prevention of Contrast Induced Nephropathy in High-Risk Adult Patients Undergoing Coronary Angiography: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Karisse Torres
2015 (Arlington) Annual Meeting
Contributed Session
Presentation of the currentness of data in DMC reports – Learnings from a Randomized Control Trial with Infrequent Study Visit
Jiang Yuan
2015 (Arlington) Annual Meeting
Contributed Session
Program-Wide DMCs Pros and Cons - the ISC point of view
Joana Sederias
2015 (Arlington) Annual Meeting
Contributed Session
REDUCING ADVERSE EVENTS REPORTING FOR COMMERCIALLY AVAILABLE AGENTS (SUNITINIB AND TEMSIROLIMUS) CAN IMPROVE PHASE II TRIAL EXECUTION
Nikki van Leeuwen
2015 (Arlington) Annual Meeting
Contributed Session
REGRESSION DISCONTINUITY DESIGN: SIMULATION AND APPLICATION IN THREE RANDOMIZED TRIALS WITH DICHOTOMOUS OUTCOMES
Kseniia Ratushna
2015 (Arlington) Annual Meeting
Contributed Session
RESEARCH OF THE TRAINING LEVEL OF CLINICAL TRIAL SPECIALISTS USING THE SELF-ASSESSMENTS SYSTEMS
Catherine Gregor
2015 (Arlington) Annual Meeting
Contributed Session
RESEARCHMATCH: AN ON-LINE REGISTRY TO CONNECT VOLUNTEERS AND CLINICAL RESEARCHERS
Christina Yap
2015 (Arlington) Annual Meeting
Contributed Session
Response-Adaptive Randomization in Multi-Arm Selection Trials: Comparison of a Frequentist and Bayesian Approach
Pradeep Singh
2015 (Arlington) Annual Meeting
Contributed Session
Robust multivariate test procedure for discrete and continuous outcome measures with application to pediatric cancer survivor study
Ruitao LIN
2015 (Arlington) Annual Meeting
Contributed Session
Robust Optimal Interval Design with an Application to Dose Finding in Drug-Combination Trials
Anne Daykin
2015 (Arlington) Annual Meeting
Contributed Session
ROLES AND DECISION MAKING OF TRIAL OVERSIGHT COMMITTEES AND THE CONTRIBUTION TO TRIAL CONDUCT: A QUALITATIVE STUDY.
Toshimitsu Hamasaki
2015 (Arlington) Annual Meeting
Contributed Session
Sample size considerations for clinical trials with two primary time-to-event outcomes
Kristian Brock
2015 (Arlington) Annual Meeting
Contributed Session
Seamless Phase I/II Adaptive Dose-finding Design with Efficacy-Toxicity Trade-offs for Targeted Therapies in Oncology
MOISÉS GÓMEZ MATEU
2015 (Arlington) Annual Meeting
Contributed Session
SELECTING THE PRIMARY ENDPOINT IN A RANDOMIZED CLINICAL TRIAL. A CARDIOVASCULAR CASE STUDY
Gaurav Sharma
2015 (Arlington) Annual Meeting
Contributed Session
Sensitivity Analysis for the Primary Outcome in a Drug Abuse Trial
Lifeng Lin
2015 (Arlington) Annual Meeting
Contributed Session
Sensitivity to excluding treatments in network meta-analysis
Karla Hemming
2015 (Arlington) Annual Meeting
Contributed Session
Setting straight the sample size determination for stepped wedge and cluster randomised trials: design effects and illustrative examples
Aenne Glass
2015 (Arlington) Annual Meeting
Contributed Session
SMALL-ANIMAL PET/CT STUDY FOR COMPARISON OF PEPTIDE RADIOTRACER CHOLINE AND BOMBESIN FOR PROSTATA CANCER IMAGING IN A PC-3 HUMAN PROSTATE CANCER XENOGRAFT MOUSE MODEL
Emily Miller
2015 (Arlington) Annual Meeting
Contributed Session
SOCIAL NETWORK ANALYSIS AND NETWORK MAPPING SHOW THE GROWTH OF COPUBLICATION NETWORKS ON THE ACTION FOR HEALTH IN DIABETES (LOOK AHEAD) CLINICAL TRIAL
Zhibao Mi
2015 (Arlington) Annual Meeting
Contributed Session
Statistical Assessment of Rescue Medication Effect in Psychiatric Clinical Trials
Mary Redman
2015 (Arlington) Annual Meeting
Contributed Session
Statistical Designs of Master Protocols and on the Design of the SWOG Lung Master Protocol(S1400; Lung-MAP)
MARION CAMPBELL
2015 (Arlington) Annual Meeting
Contributed Session
STEPPED WEDGE DESIGNS OR STANDARD CLUSTER TRIAL DESIGNS FOR EVALUATING HEALTHCARE INTERVENTIONS?
Lydia Foster
2015 (Arlington) Annual Meeting
Contributed Session
Stopping Early in a Non-Inferiority Trial When the Primary Efficacy Outcome is also the Primary Safety Outcome
Nicole Butler
2015 (Arlington) Annual Meeting
Contributed Session
Streamlining Event Adjudication: Moving from a Paper-based to Web-based System
Alexandra Stout
2015 (Arlington) Annual Meeting
Contributed Session
STREAMLINING PROTOCOL DESIGN: THE COST OF COMPLEXITY
Dorothee Arenz
2015 (Arlington) Annual Meeting
Contributed Session
Strengthening Clinical Research through Institutionalized Clinical Conduct Management
Wenle Zhao
2015 (Arlington) Annual Meeting
Contributed Session
Subject Randomization in Studies with Unequal Allocation
Petra Schmalz
2015 (Arlington) Annual Meeting
Contributed Session
SUCCESSFUL ESTABLISHMENT OF CLINICAL RESEARCH STRUCTURES AT UNIVERSITY HOSPITAL COLOGNE BY PUBLIC FUNDING
Chris Cook
2015 (Arlington) Annual Meeting
Contributed Session
TECHNICAL IMPLEMENTATION OF THE SWOG LUNG MASTER PROTOCOL (S1400; LUNG-MAP)
Lee McDaniel
2015 (Arlington) Annual Meeting
Contributed Session
Testing Proportional and Additive Hazards Assumptions
Dikla Blumberg
2015 (Arlington) Annual Meeting
Contributed Session
THE DEVELOPMENT OF A REAL-TIME PROTOCOL DEVIATION NOTIFICATION, TRACKING AND RESOLUTION PROCESS IN MULTI-SITE SUBSTANCE USE TREATMENT CLINICAL TRIALS
Olympia Papachristofi
2015 (Arlington) Annual Meeting
Contributed Session
THE HUMAN FACTOR IN COMPLEX SURGICAL INTERVENTIONS: ASSESSING THE IMPACT OF SURGEON LEARNING CURVES.
Rebecca Lewis
2015 (Arlington) Annual Meeting
Contributed Session
THE IMPACT OF A SURVEY CONDUCTED TO INFORM DEVELOPMENT OF A COMPLEX INTERVENTION TRIAL IN MUSCLE INVASIVE BLADDER CANCER (MIBC)
Gillian Gresham
2015 (Arlington) Annual Meeting
Contributed Session
The Impact of Treatment Cycle on Protocol Completion in Randomized Clinical Trials
Michelle Snape
2015 (Arlington) Annual Meeting
Contributed Session
THE IMPLEMENTATION AND UTILITY OF SCREENING LOGS IN A RANDOMISED CONTROLLED TRIAL OF PERI-OPERATIVE CHEMOTHERAPY OR SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (POUT - CRUK/11/027)
Zhiying You
2015 (Arlington) Annual Meeting
Contributed Session
The minimum required number of clusters with unequal cluster sizes in cluster randomized trials
Eve Jelstrom
2015 (Arlington) Annual Meeting
Contributed Session
THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK (CTN) INVESTIGATOR TOOLBOX PROJECT: RESOURCES FOR CLINICAL TRIALS MANAGEMENT
Eric Foster
2015 (Arlington) Annual Meeting
Contributed Session
THE NETWORK FOR EXCELLENCE IN NEUROSCIENCE CLINICAL TRIALS (NeuroNEXT) PROTOCOL WORKING GROUP DESIGN PHASE EXPERIENCES
Amy Ruppert
2015 (Arlington) Annual Meeting
Contributed Session
The Relationship among Toxicity, Response, and Survival Profiles Ultimately Influence Calling a Beneficial Experimental Drug Favorable under Standard Phase I, II, and III Clinical Trial Designs
Kevin Wilson
2015 (Arlington) Annual Meeting
Contributed Session
THE USE OF OPEN-SOURCE WEB-BASED TOOLS TO FACILITATE AND SUPPORT AN MRI IMAGING STUDY OF ANTERIOR VAGINAL WALL DESCENT IN WOMEN WITH PELVIC ORGAN PROLAPSE.
James Martin
2015 (Arlington) Annual Meeting
Contributed Session
The use of simulation to examine the effects of varying cluster size on the power of stepped wedge cluster randomised trials
Robbie Wilson
2015 (Arlington) Annual Meeting
Contributed Session
Timing is everything: Experience from Integrating Drug Supply Management (DSM) systems into eCRF systems.
Aenne Glass
2015 (Arlington) Annual Meeting
Contributed Session
To improve the prediction of procedural success after aortic valve implantation: A pilot study (N=60) to identify unconventional, approach-related predictors
Agnieshka Baumritter
2015 (Arlington) Annual Meeting
Contributed Session
TRAINING AND CERTIFICATION OF NON-PHYSICIANS FOR DETECTING REFERRAL-WARRANTED RETINOPATHY OF PREMATURITY IN THE TELEMEDICINE APPROACHES TO EVALUATING ACUTE-PHASE RETINOPATHY OF PREMATURITY (E-ROP) STUDY
Athanasia Gravani
2015 (Arlington) Annual Meeting
Contributed Session
Training of staff within Randomized Controlled Trials (RCTs) of health-care interventions: a systematic review of the literature
Jeannette Lee
2015 (Arlington) Annual Meeting
Contributed Session
TREATMENT OF MALE PARTNERS TO PREVENT RECURRENT BACTERIAL VAGINOSIS IN WOMEN
Shelly Lensing
2015 (Arlington) Annual Meeting
Contributed Session
Two-Stage Phase II Design for Simultaneously Evaluating Efficacy and Toxicity of an Anti-Angiogenic Agent for Treating Kaposi Sarcoma
Shelly Lensing
2015 (Arlington) Annual Meeting
Contributed Session
Two-Stage Phase II Design without Suspending Accrual for Interim Analysis
Jenny Donovan
2015 (Arlington) Annual Meeting
Contributed Session
Understanding recruitment to randomized clinical trials: clear obstacles and hidden challenges for recruiters
Olympia Papachristofi
2015 (Arlington) Annual Meeting
Contributed Session
UNRAVELLING THE COMPLEXITIES IN THE ASSESSMENT OF SURGICAL INTERVENTIONS: DECOMPOSING THE COMPLEX STRUCTURE AND ACCOUNTING FOR MULTIPLE PROVIDERS.
Leah Forman
2015 (Arlington) Annual Meeting
Contributed Session
USE OF AN ANDROID PHONE APP FOR AUTOMATED TEXT MESSAGING IN INTERNATIONAL SETTINGS
Sohail Mulla
2015 (Arlington) Annual Meeting
Contributed Session
Use of core outcome domains among chronic pain clinical trials
Carley Prynn
2015 (Arlington) Annual Meeting
Contributed Session
Use of Internet Technology for Training, Certification, and Monitoring in the Gulf Long-Term Follow-up Study (GuLF STUDY)
Sharon Kean
2015 (Arlington) Annual Meeting
Contributed Session
Using routinely collected datasets (primary and secondary care) for multi-centre clinical trials
Matthew Curry
2015 (Arlington) Annual Meeting
Contributed Session
Utility of a Participant Survey to Assess the Feasibility of a Follow-up Clinical Exam in the Gulf Long-Term Follow-up STUDY (GuLF STUDY)
Elizabeth Sugar
2015 (Arlington) Annual Meeting
Contributed Session
Utilizing Clinical Trials to Assess Cost-Effectiveness: Lessons from the MUST Trial
Ira Katz
2015 (Arlington) Annual Meeting
Contributed Session
VA Cooperative Study # 590: Double-Blind Placebo-Controlled Study of Lithium for Preventing Repeated Suicidal Self-Directed Violence in Patients with Depression or Bipolar Disorder
Anil Kumar
2015 (Arlington) Annual Meeting
Contributed Session
WEBREPORTER - An Automated Solution for Clinical Trials Web Reporting
Jonathan Shtaynberger
2015 (Arlington) Annual Meeting
Contributed Session
What is the most popular dose-finding design for phase I oncology trials?
Benjamin Rouse
2015 (Arlington) Annual Meeting
Contributed Session
WOULD NETWORK META-ANALYSIS HAVE CHANGED CLINICAL PRACTICE GUIDELINE RECOMMENDATIONS? A CASE STUDY ON FIRST-LINE MEDICAL THERAPIES FOR PRIMARY OPEN-ANGLE GLAUCOMA